LDS/Medical Tests/Post-transplant Test for Kidney Acute Rejection (VitaGraft™, Tuteva™)

Post-transplant Test for Kidney Acute Rejection (VitaGraft™, Tuteva™)

Each year, over 100,000 individuals worldwide undergo kidney transplantation to manage ESRD. Despite advances in immunosuppressive therapy (e.g., cyclosporine, tacrolimus, anti-thymocyte globulin), acute rejection remains a critical barrier to long-term graft survival, affecting approximately 10–20% of transplant recipients within the first year.

The current gold standard for diagnosing acute rejection is a renal biopsy, often combined with monitoring serum creatinine and urea levels. However, these methods are invasive, carry procedural risks, and lack early predictive power.

Tuteva™ is a non-invasive, blood-based molecular test developed by VericiDx. It assesses the risk of acute kidney rejection by measuring gene expression profiles in peripheral blood using next-generation RNA sequencing (RNA-Seq). Studies demonstrate Tuteva™ has a higher positive predictive value compared to traditional blood biomarkers (Transplant Direct, 2022). More information: VericiDx Tuteva™ https://vericidx.com/.

  • Risk assessment for acute rejection at 3, 12, and 24-month post-transplant
  • Supports early intervention strategies, minimizing unnecessary biopsies

Results are reported as a quantitative risk score.

Patients are stratified into low-risk and high-risk categories.

Interpretation Caveats:

  • A high-risk result suggests elevated probability of acute rejection but is not diagnostic.
  • A low-risk result does not entirely exclude rejection but indicates reduced likelihood.

    High-risk

  • Consider intensified monitoring, potential biopsy.

    Low-risk

  • Continue standard monitoring protocols.

Not applicable

Next-generation RNA sequencing.

Whole blood (EDTA).

Stability

  • Ambient: up to 48 hours
  • Refrigerated: up to 5 days.
Urea, creatinine, albumin creatinine ration, urine microalbumin, 24 hours urinary protein, electrolytes.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login